Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations

Fineline Cube Mar 31, 2026
Company Deals

Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline

Fineline Cube Mar 31, 2026
Company Deals

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

Fineline Cube Mar 30, 2026
Company Deals

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Fineline Cube Mar 30, 2026
Company Deals

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Fineline Cube Mar 30, 2026
Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Fineline Cube Mar 31, 2026
Company Drug

NMPA Approves GSK’s Exdensur as First Ultra-Long-Acting Biologic for Severe Eosinophilic Asthma

Fineline Cube Mar 31, 2026
Company Drug

Kexing Biopharma Secures FDA Clearance for GB19 Clinical Trial in Lupus, Targeting Novel BDCA2 Pathway

Fineline Cube Mar 31, 2026
Company Drug

Sanofi’s Sarclisa Receives CHMP Recommendation for Newly Diagnosed Multiple Myeloma

Fineline Cube Nov 15, 2024

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that the Committee for Medicinal Products for...

Company Deals Medical Device

J&J MedTech Secures Exclusive Distribution Deal with Responsive Arthroscopy

Fineline Cube Nov 15, 2024

Johnson & Johnson (J&J, NYSE: JNJ) MedTech, a leading player in the US medical technology...

Company Drug

Jiangsu Hengrui Receives NMPA Approval for SHR-2173 Clinical Trial in ITP

Fineline Cube Nov 15, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from...

Company Drug

Eisai and Biogen’s Lecanemab Receives Positive CHMP Opinion for Early Alzheimer’s Treatment

Fineline Cube Nov 15, 2024

Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have jointly announced that the...

Policy / Regulatory

Merck Secures Exclusive Rights to LaNova’s PD-1/VEGF Bispecific Antibody LM-299

Fineline Cube Nov 15, 2024

US pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced a significant...

Policy / Regulatory

China Releases Comprehensive AI Application Guidelines for Healthcare Industry

Fineline Cube Nov 15, 2024

The National Health Commission, National Administration of Traditional Chinese Medicine, and National Bureau of Disease...

Company

BeiGene Ltd to Become BeOne Medicines Ltd, Emphasizing Global Oncology Commitment

Fineline Cube Nov 15, 2024

China-based biotechnology company BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced a proposed...

Company Deals

Beijing Biostar Partners with Baheal for Utidelone Market Promotion in China

Fineline Cube Nov 15, 2024

Beijing Biostar Technologies Ltd (HKG: 2563), a synthetic biology-driven anti-tumor drug specialist that made its...

Policy / Regulatory

NMPA Issues Interim Provisions for Overseas MAHs’ Designated Domestic Responsible Persons

Fineline Cube Nov 15, 2024

The National Medical Products Administration (NMPA) has released the “Interim Provisions on the Management of...

Company Drug

Sino Biopharmaceutical’s TQB3002 Receives FDA Clearance for Phase I Study

Fineline Cube Nov 15, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading China-based pharmaceutical company, has announced that it has...

Company Deals

PegBio Files for IPO on Hong Kong Stock Exchange

Fineline Cube Nov 15, 2024

PegBio Co., Ltd., a specialist in endocrine metabolism based in Suzhou, has taken a significant...

Company Drug

Mabwell Bioscience Receives NMPA Approval for 9MW2821 Clinical Trials

Fineline Cube Nov 15, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced that it...

Company Drug

WuXi Biologics Expands Sterile Filling Capabilities in Germany with New Line

Fineline Cube Nov 15, 2024

China’s Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced plans...

Company Drug

Jiangxi Jemincare’s JMX-2002 Liposome Injection Gets NMPA Clinical Clearance

Fineline Cube Nov 15, 2024

Jiangxi Jemincare Group, a China-based pharmaceutical company, has announced that it has received clinical clearance...

Company Drug

Lion TCR Gains NMPA Approval for mRNA TCR-T Therapy GZL-016 in HCC

Fineline Cube Nov 15, 2024

Singapore-based clinical-stage biotechnology company Lion TCR, supported by Chinese investors, has secured tacit clinical approval...

Company

BeiGene to Rebrand as BeOne Medicines, Emphasizing Global Commitment to Cancer Care

Fineline Cube Nov 15, 2024

BeiGene Ltd. (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading global innovator in oncology treatments,...

Company Drug

Eli Lilly’s Tirzepatide Shows Sustained Weight Loss in 176-Week Study

Fineline Cube Nov 14, 2024

US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has released 176-week follow-up data from...

Company Medical Device

GE Healthcare’s SIGNA MAGNUS MRI Scanner Receives FDA 510(k) Clearance

Fineline Cube Nov 14, 2024

US medical device and life sciences leader GE Healthcare Technologies Inc. (NASDAQ: GEHC) has announced...

Company Deals

Cullgen and Pulmatrix Merge to Form Nasdaq-Listed Protein Degradation Company

Fineline Cube Nov 14, 2024

Cullgen Inc., a clinical-stage biopharmaceutical company with operations in China, the US, and Japan, is...

Company Drug

ImmuneOnco Initiates Phase II Study for IMM27M in ER+ Advanced Breast Cancer

Fineline Cube Nov 14, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a leading biopharmaceutical company specializing in immuno-oncology, has...

Posts pagination

1 … 244 245 246 … 643

Recent updates

  • AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations
  • Roche Launches cobas MPX-E Test in CE Markets, Consolidating Four-Virus Detection for Enhanced Blood Safety
  • NMPA Approves GSK’s Exdensur as First Ultra-Long-Acting Biologic for Severe Eosinophilic Asthma
  • Kexing Biopharma Secures FDA Clearance for GB19 Clinical Trial in Lupus, Targeting Novel BDCA2 Pathway
  • Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations

Medical Device

Roche Launches cobas MPX-E Test in CE Markets, Consolidating Four-Virus Detection for Enhanced Blood Safety

Company Drug

NMPA Approves GSK’s Exdensur as First Ultra-Long-Acting Biologic for Severe Eosinophilic Asthma

Company Drug

Kexing Biopharma Secures FDA Clearance for GB19 Clinical Trial in Lupus, Targeting Novel BDCA2 Pathway

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.